Epitope Mapping and Fine Specificity of Human T and B Cell Responses for Novel Candidate Blood-Stage Malaria Vaccine P27A.
Kristina M Geiger, Daniel Guignard, Che Yang, Jean-Pierre Bikorimana, Bruno E Correia, Sophie Houard, Catherine Mkindi, Claudia A Daubenberger, François Spertini, Giampietro Corradin and 1 more
Open access · goldAbstract readClinical Trial, Phase I
Article in Frontiers in immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 97% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 1 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
11 authors at 7 institutions in 4 countries.
Kristina M GeigerBiochemistry Department, University of Lausanne, Epalinges, Switzerland.
Daniel GuignardBiochemistry Department, University of Lausanne, Epalinges, Switzerland.
Che YangInstitute of Bioengineering, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland.
Jean-Pierre BikorimanaDivision of Immunology and Allergy, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
Bruno E CorreiaInstitute of Bioengineering, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland.
Sophie HouardEuropean Vaccine Initiative, Heidelberg, Germany.
Catherine MkindiSwiss Tropical and Public Health Institute, Basel, Switzerland.
Claudia A DaubenbergerSwiss Tropical and Public Health Institute, Basel, Switzerland.
François SpertiniDivision of Immunology and Allergy, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
Giampietro CorradinBiochemistry Department, University of Lausanne, Epalinges, Switzerland.
Régine AudranDivision of Immunology and Allergy, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
University Hospital of Lausanne · CHUniversity of Basel · CHUniversity of Lausanne · CHÉcole Polytechnique Fédérale de Lausanne · CHSIB Swiss Institute of Bioinformatics · CHUniversity of California, Berkeley · USVienna Vaccine Safety Initiative · DE
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
P27A is a novel synthetic malaria vaccine candidate derived from the blood stage
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Epitope Mapping and Fine Specificity of Human T and B Cell Responses for Novel Candidate Blood-Stage Malaria Vaccine P27A. · full record | OpenQuestion